Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Bioavailability of XC8 10 mg vs 40 mg in Healthy Volunteers
NCT05558462Phase 1Completed
- Sponsor
- Valenta Pharm
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of histamine glutarimide in influenza and respiratory viral infection (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 3 more. Started Aug 2022; status: completed.
02
Drugs
histamine glutarimide
03
Conditions
influenzarespiratory viral infection
Beyond the preview
Go deeper on NCT05558462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558462.